Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. (Q37102828)
Jump to navigation
Jump to search
scientific article published on 08 August 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. |
scientific article published on 08 August 2011 |
Statements
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation (English)
J P Clancy
Steven M Rowe
Frank J Accurso
Moira L Aitken
Raouf S Amin
Melissa A Ashlock
Manfred Ballmann
Inez Bronsveld
Preston W Campbell
Kris De Boeck
Scott H Donaldson
Henry L Dorkin
Jordan M Dunitz
Peter R Durie
Manu Jain
Anissa Leonard
Karen S McCoy
Richard B Moss
Joseph M Pilewski
Daniel B Rosenbluth
Michael S Schechter
Martyn Botfield
Claudia L Ordoñez
George T Spencer-Green
Laurent Vernillet
Steve Wisseh
Karl Yen
Michael W Konstan
1 reference